Migraine

CTAF

Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.

Interventions of interest, July 2018 review:

  • Erenumab (Amgen/Novartis)
  • Fremanezumab (Teva)
  • Galcanezumab (Eli Lilly)

Interventions of interest, July 2014 review:

  • OnabotulinumtoxinA (Botox®, Allergan, Inc)
  • Transcutaneous electrical nerve stimulation (Cefaly®, Cefaly Technology)
  • Single pulse transcranial magnetic stimulation (SpringTMS™, eNeura Inc.)

 

ASSOCIATED MEETING & MATERIALS

CTAF
June 14, 2018 10am - 4pm PT

LA Renaissance Airport Hotel
9620 Airport Blvd
Los Angeles, CA 90045

CTAF will convene to review ICER's report on CGRP inhibitors for prevention of migraine headaches.

To watch the live webcast, beginning at 10am PT, visit http://www.beaconliveweb.com/join?jrd=aWNlcjJ8OTc5Nzk3fElDRVJ8QXR0ZW5kZWV8IHwgfA

Key Dates

Associated Materials

11/09/2017 – 11/30/2017

12/04/2017

12/04/2017

12/04/2017 – 12/22/2017

01/09/2018

03/02/2018

03/02/2018

04/11/2018

ICER’s Draft Evidence Report on erenumab for migraine, open to public comment until May 8, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.


04/11/2018

04/11/2018 – 05/08/2018

05/31/2018

05/31/2018

05/31/2018

06/14/2018

06/14/2018

07/05/2018
Final Evidence Report and Meeting Summary


ASSOCIATED MEETING & MATERIALS

CTAF
July 11, 2014 10:00AM-4:00PM (PST)

Sheraton Gateway Hotel, Los Angeles, CA

CTAF examined various treatment options for migraine headaches. CTAF's review included evidence on the use of Botox for prevention and on the use of opioids for treatment in the emergency room. Also briefly reviewed were a new device for the prevention of migraines (Cefaly) and one for the treatment of migraines (SpringTMS by eNeura). CTAF’s public deliberation of the evidence will provide clarity and guidance to clinicians, insurers, and patients confronted with decisions on treatment of migraines.

Key Dates

Associated Materials

06/13/2014

06/13/2014

07/11/2014

07/11/2014

07/18/2014

Public comments received on the Draft Evidence Report.


08/19/2014
Action Guide For Patients

08/19/2014
Action Guide For Clinicians

08/19/2014
Action Guide For Payers and Policymakers

Other Materials